Amgen warns against TRC mini-tender offer

THOUSAND OAKS, Calif. – Amgen Inc. (Nasdaq: AMGN) has recommended that shareholders reject a bid by TRC Capital Corp. to purchase up to 1.5 million shares of the pharmaceutical company’s common stock at $53.75 per share. Amgen is not associated with and does not endorse the mini-tender offer by TRC, which it said “has made…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -